XML 55 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements of Operations (Unaudited) (USD $)
 3 Months Ended 6 Months Ended
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2013
Jun. 30, 2012
Revenues:        
License fee and milestone revenue $ 14,311 $ 20,907 $ 28,570 $ 45,745
License fee and milestone revenue from affiliated entity 106,250 106,250 212,500 212,500
Grants and miscellaneous revenue 665,049 308,925 1,999,765 1,870,958
Total revenues 785,610 436,082 2,240,835 2,129,203
Operating expenses:        
Research and development 4,411,082 4,527,086 9,526,194 8,569,665
General and administrative 3,046,586 2,696,909 6,020,739 5,184,997
Gain (Loss) on Disposition of Assets 1,000,000 0 1,000,000 651,000
Gain on sale of assets     (1,000,000) (651,000)
Total operating expenses 6,457,668 7,223,995 14,546,933 13,103,662
Loss from operations (5,672,058) (6,787,913) (12,306,098) (10,974,459)
Other income (expense):        
Interest and other income, net 37,391 41,036 76,851 72,580
Change in fair value of common stock warrants (3,199,878) 3,594,782 (4,627,494) 46,609
Loss on investment in affiliated entity (2,032,051) (992,373) (2,868,135) (1,553,917)
Net loss (10,866,596) (4,144,468) (19,724,876) (12,409,187)
Net loss attributable to non-controlling interest 14,008 11,289 28,168 21,059
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (10,852,588) $ (4,133,179) $ (19,696,708) $ (12,388,128)
Loss per common share—basic and diluted:        
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders (in USD per share) $ (0.06) $ (0.03) $ (0.12) $ (0.09)
Weighted average number of common shares outstanding—basic and diluted 179,954,816 134,968,394 168,187,315 134,968,394